Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dithranol + fluocinonide is a topical combination therapy used primarily for the treatment of chronic plaque psoriasis. Dithranol (also known as anthralin) is an anthracene derivative that impairs DNA replication and decreases cell division, leading to reduced proliferation of keratinocytes in psoriatic plaques[3][7]. Fluocinonide is a potent synthetic corticosteroid that acts as an anti-inflammatory agent by activating glucocorticoid receptors, thereby reducing swelling, redness, and itching associated with inflammatory skin conditions such as psoriasis[4][8][10]. The combination aims to provide more rapid initial clearance of psoriatic lesions and reduce burning sensations compared to dithranol alone; however, it may be associated with more rapid relapse after discontinuation[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dithranol + fluocinonide.